GLP-1激动剂与选择性上镜检查时肺误吸的风险:一项系统回顾和荟萃分析。

Q3 Medicine
Open Respiratory Medicine Journal Pub Date : 2025-06-11 eCollection Date: 2025-01-01 DOI:10.2174/0118743064372550250603061720
Praveen Reddy Elmati, Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Andres Perez, Ruman K Qasba, Yatinder Bains, Mehul Shah, Salim Surani
{"title":"GLP-1激动剂与选择性上镜检查时肺误吸的风险:一项系统回顾和荟萃分析。","authors":"Praveen Reddy Elmati, Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Andres Perez, Ruman K Qasba, Yatinder Bains, Mehul Shah, Salim Surani","doi":"10.2174/0118743064372550250603061720","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like Peptide-1 (GLP-1) agonists cause delayed gastric emptying by acting on vagal afferent nerves. Retained gastric contents (RGC) increase the risk of pulmonary aspiration, particularly under anesthesia in endoscopic procedures. This systematic review and meta-analysis aim to summarize the current evidence on pulmonary aspiration in patients receiving GLP-1 agonists undergoing endoscopy.</p><p><strong>Methods: </strong>A systematic review was conducted using Cochrane, Embase, and PubMed from inception to May 2024, including studies and case reports examining GLP-1 agonists and pulmonary aspiration. Data on study characteristics, patient demographics, and GLP-1 agonist use were collected. A pooled analysis of retrospective studies was performed using RevMan version 5.4.1. The study protocol was registered in the PROSPERO database (ID CRD42024595241).</p><p><strong>Results: </strong>A total of five case reports involving six patients and twelve studies including 210,216 patients were identified. Pulmonary aspiration occurred in 143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group. Notably, three patients experienced aspiration despite stopping GLP-1 agonists more than six days prior and fasting for over eight hours. The meta-analysis showed an odds ratio of 1.23 (P = 0.59; 95% CI, 0.58 to 2.60) for pulmonary aspiration associated with GLP-1 agonist use, which was not statistically significant.</p><p><strong>Discussion: </strong>This analysis did not find a statistically significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopic procedures. While the findings align with some existing studies suggesting minimal increased risk, the presence of aspiration cases despite prolonged fasting highlights potential gaps in current peri-procedural management. Limitations include reliance on retrospective data and case reports, as well as variability in fasting protocols.</p><p><strong>Conclusion: </strong>The study found no significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopy. Further research is warranted to develop evidence-based fasting guidelines and optimize peri-procedural management for patients on GLP-1 agonists.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"19 ","pages":"e18743064372550"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481593/pdf/","citationCount":"0","resultStr":"{\"title\":\"GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.\",\"authors\":\"Praveen Reddy Elmati, Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Andres Perez, Ruman K Qasba, Yatinder Bains, Mehul Shah, Salim Surani\",\"doi\":\"10.2174/0118743064372550250603061720\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Glucagon-like Peptide-1 (GLP-1) agonists cause delayed gastric emptying by acting on vagal afferent nerves. Retained gastric contents (RGC) increase the risk of pulmonary aspiration, particularly under anesthesia in endoscopic procedures. This systematic review and meta-analysis aim to summarize the current evidence on pulmonary aspiration in patients receiving GLP-1 agonists undergoing endoscopy.</p><p><strong>Methods: </strong>A systematic review was conducted using Cochrane, Embase, and PubMed from inception to May 2024, including studies and case reports examining GLP-1 agonists and pulmonary aspiration. Data on study characteristics, patient demographics, and GLP-1 agonist use were collected. A pooled analysis of retrospective studies was performed using RevMan version 5.4.1. The study protocol was registered in the PROSPERO database (ID CRD42024595241).</p><p><strong>Results: </strong>A total of five case reports involving six patients and twelve studies including 210,216 patients were identified. Pulmonary aspiration occurred in 143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group. Notably, three patients experienced aspiration despite stopping GLP-1 agonists more than six days prior and fasting for over eight hours. The meta-analysis showed an odds ratio of 1.23 (P = 0.59; 95% CI, 0.58 to 2.60) for pulmonary aspiration associated with GLP-1 agonist use, which was not statistically significant.</p><p><strong>Discussion: </strong>This analysis did not find a statistically significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopic procedures. While the findings align with some existing studies suggesting minimal increased risk, the presence of aspiration cases despite prolonged fasting highlights potential gaps in current peri-procedural management. Limitations include reliance on retrospective data and case reports, as well as variability in fasting protocols.</p><p><strong>Conclusion: </strong>The study found no significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopy. Further research is warranted to develop evidence-based fasting guidelines and optimize peri-procedural management for patients on GLP-1 agonists.</p>\",\"PeriodicalId\":39127,\"journal\":{\"name\":\"Open Respiratory Medicine Journal\",\"volume\":\"19 \",\"pages\":\"e18743064372550\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481593/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Respiratory Medicine Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0118743064372550250603061720\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Medicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118743064372550250603061720","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

胰高血糖素样肽-1 (GLP-1)激动剂通过作用于迷走传入神经引起胃排空延迟。胃内容物残留(RGC)增加了肺误吸的风险,特别是在内镜手术麻醉下。本系统综述和荟萃分析旨在总结目前在接受GLP-1激动剂的患者接受内窥镜检查时肺误吸的证据。方法:从成立到2024年5月,通过Cochrane、Embase和PubMed进行系统综述,包括GLP-1激动剂和肺误吸的研究和病例报告。收集研究特征、患者人口统计数据和GLP-1激动剂使用数据。采用RevMan 5.4.1版本对回顾性研究进行汇总分析。研究方案已在PROSPERO数据库中注册(ID CRD42024595241)。结果:共纳入5份病例报告,涉及6例患者;12项研究,涉及210,216例患者。GLP-1激动剂组87,691例患者中有143例(0.16%)发生肺误吸,安慰剂组122,525例患者中有149例(0.12%)发生肺误吸。值得注意的是,3名患者在停用GLP-1激动剂6天以上并禁食超过8小时后仍出现误吸。荟萃分析显示,与GLP-1激动剂使用相关的肺误吸的优势比为1.23 (P = 0.59; 95% CI, 0.58至2.60),无统计学意义。讨论:该分析未发现GLP-1激动剂的使用与内窥镜手术中肺误吸风险之间有统计学意义的关联。虽然这些发现与一些现有研究一致,表明风险增加很小,但长期禁食后仍存在误吸病例,这凸显了当前围手术期管理的潜在差距。局限性包括对回顾性数据和病例报告的依赖,以及禁食方案的可变性。结论:研究发现GLP-1激动剂的使用与内窥镜检查时肺部误吸风险无显著相关性。需要进一步的研究来制定基于证据的禁食指南,并优化GLP-1激动剂患者的围手术期管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.

GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.

GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.

GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.

Introduction: Glucagon-like Peptide-1 (GLP-1) agonists cause delayed gastric emptying by acting on vagal afferent nerves. Retained gastric contents (RGC) increase the risk of pulmonary aspiration, particularly under anesthesia in endoscopic procedures. This systematic review and meta-analysis aim to summarize the current evidence on pulmonary aspiration in patients receiving GLP-1 agonists undergoing endoscopy.

Methods: A systematic review was conducted using Cochrane, Embase, and PubMed from inception to May 2024, including studies and case reports examining GLP-1 agonists and pulmonary aspiration. Data on study characteristics, patient demographics, and GLP-1 agonist use were collected. A pooled analysis of retrospective studies was performed using RevMan version 5.4.1. The study protocol was registered in the PROSPERO database (ID CRD42024595241).

Results: A total of five case reports involving six patients and twelve studies including 210,216 patients were identified. Pulmonary aspiration occurred in 143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group. Notably, three patients experienced aspiration despite stopping GLP-1 agonists more than six days prior and fasting for over eight hours. The meta-analysis showed an odds ratio of 1.23 (P = 0.59; 95% CI, 0.58 to 2.60) for pulmonary aspiration associated with GLP-1 agonist use, which was not statistically significant.

Discussion: This analysis did not find a statistically significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopic procedures. While the findings align with some existing studies suggesting minimal increased risk, the presence of aspiration cases despite prolonged fasting highlights potential gaps in current peri-procedural management. Limitations include reliance on retrospective data and case reports, as well as variability in fasting protocols.

Conclusion: The study found no significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopy. Further research is warranted to develop evidence-based fasting guidelines and optimize peri-procedural management for patients on GLP-1 agonists.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Open Respiratory Medicine Journal
Open Respiratory Medicine Journal Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.70
自引率
0.00%
发文量
17
期刊介绍: The Open Respiratory Medicine Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in respiratory medicine. Topics covered include: -COPD- Occupational disorders, and the role of allergens and pollutants- Asthma- Allergy- Non-invasive ventilation- Therapeutic intervention- Lung cancer- Lung infections respiratory diseases- Therapeutic interventions- Adult and paediatric medicine- Cell biology. The Open Respiratory Medicine Journal, a peer reviewed journal, is an important and reliable source of current information on important recent developments in the field. The emphasis will be on publishing quality articles rapidly and making them freely available worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信